References
- The Cancer Registry of Norway. Survival of cancer patients. Cases diagnosed in Norway 1968–1975. The Registry, Oslo 1976
- Enblad P, Adami H-O, Bergström R, et al. Improved survival of patients with cancers of the colon and rectum. J Natl Cancer Inst 1988; 80: 586–91
- Kewenter J, Björck S, Haglind E, et al. Screening and rescreen-ing for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer 1988; 62: 645–51
- Hardcastle J D, Chamberlain J, Sheffield J, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer. Results for first 107,349 subjects. Lancet 1989; 1: 1160–3
- Kronborg O, Fenger C, Olsen J, Bech K, Søndergaard O. Repeated screening for colorectal cancer with fecal occult blood test. A prospective randomised study at Funen, Denmark. Scand J Gastroenterol 1989; 24: 599–606
- Faivre J, Arveux P, Milan C, et al. Participation in mass screening for colorectal cancer: results of screening and rescreening from the Burgundy study. Eur J Cancer Prev 1991; 1: 49–55
- Mandel J S, Bond J H, Church T R, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365–71
- Kewenter J, Brevinge H, Engarås B, et al. Follow-up after screening for colorectal neoplasms with fecal occult blood testing in a controlled trial. Dis Col Rect 1994, In press
- Lehman E L. Testing statistical hypothesis. Wiley, New York 1959
- Maxwell A E. Analyzing qualitative data. Methuen, London 1961; 63–72
- Wahlström J, Witt-Engerström I, Mellquist L, Anvret M, Oden A. Rett syndrome related to fragile X (P22) in caffeine-induced lymphocyte culture. Brain Dev 1990; 12: 128–30
- Cancer incidence in Sweden 1988. Socialstyrelsen, Stockholm 1988
- Thomas W M, Pye G, Hardcastle J D, et al. Role of dietary restriction in Haemoccult screening for colorectal cancer. Br J Surg 1989; 76: 976–8
- Thomas W M, Pye G, Hardcastle J D, et al. Faecal occult blood screening for colorectal neoplasia: a randomized trial of three days or six days of tests. Br J Surg 1990; 77: 277–9
- Kewenter J, Engarås B, Haglind E, et al. Value of retesting subjects with a positive Hemoccult in screening for colorectal cancer. Br J Surg 1990; 77: 1349–51
- Thomas M, Pye G, Hardcastle J D, et al. Screening for colorectal carcinomas: an analysis of the sensitivity of Haemoccult. J Surg 1992; 79: 833–5
- Walker A R, Whynes D K, Hardcastle J D. Rehydration of guaiac-based faecal occult blood tests in mass screening for colorectal cancer. J Gastroenterol 1991; 26: 215–8
- Jensen J, Kewenter J, Asztély M, et al. Double contrast barium enema and flexible rectosigmoidoscopy: a reliable diagnostic combination for detection of colorectal neoplasm. Br J Surg 1990; 77: 270–2
- Church T R, Mandel J S, Bond J H, . Colon cancer control study: status and current issues. Cancer screening, A B Miller, J Chamberlain, N E Day, M Hakama, P C Porok, et al. UICC Cambridge University, Cambridge 1991; 83–106
- Möller Jensen B, Kronborg O, Fenger C. Interval cancers in screening with fecal occult blood test for colorectal cancer. Scand J Gastroenterol 1992; 27: 779–82
- Andersson I, Aspegren K, Janzon L, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. Br Med J 1988; 297: 943–8